DOTATOC PET/CT for Imaging NET Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Insulinoma
- Carcinoid
- Ganglioneuroma
- Gastrinoma
- Vipoma
- Glucagonoma
- Pituitary Adenoma
- Paraganglioma
- Medullary Carcinoma
- Pheochromocytoma
- Medulloblastoma
- Meningioma
- Small Cell Lung Cancer
- Merkel Cell Carcinoma
- Neuroblastoma
- Neuroendocrine Tumors
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 100 years
- Gender
- Both males and females
Description
Each subject will have two PET/CT scans, one using 68Ga-DOTATOC and the other using 18-Fluoride-Fluorodeoxyglucose (18F-FDG). The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has be...
Each subject will have two PET/CT scans, one using 68Ga-DOTATOC and the other using 18-Fluoride-Fluorodeoxyglucose (18F-FDG). The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada. After providing informed written consent subjects will complete a medical history questionnaire. Monitoring of adverse events There will be short-term evaluation of adverse events by comparison of vital signs before and after administration of 68Ga-DOTATOC. Twenty-four hours after 68Ga-DOTATOC administration the study coordinator will call the patient and see if they have experienced any adverse events during that time period and complete the adverse event questionnaire found in section 9.6. Follow-up Assessments The following information will be collected up to 3 years following the PET/CT scans: Initiation of a new treatment Laboratory results and pathology reports Results of imaging studies Final clinical diagnosis by physician and relevant clinical notes The study is expected to take approximately 4 years for accrual.
Tracking Information
- NCT #
- NCT03583528
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Francois Benard, MD BC Cancer